Abstract
ABSTRACT Objective Using ultrasound (US) techniques to determine the role of the intensity of the blood flow (BF) of breast tumors as a criterion of efficiency ACnPCT. Methods 30 patients aged 50-62 years with verified BC, who were candidates for 3 courses of AC-nPCT, were carried out color-coded US in the triplex mode scanning and power doppler. Luminal A Luminal B HER2(+) Triple-negative T2N0M0 3 1 - 2 T2N1M0 3 2 2 2 T3N0M0 3 4 1 3 T3N1M0 1 1 - 2 Average systolic blood flow velocity, ACBFL (cm/sec) 14,2 ± 2,6 15,9 ± 3,9 14,6 ± 2,5 16,2 ± 2,8 Measurements were made of resistance index (IR), pulsating index (IP). Results ACBFV is increased and corresponds to the malignancy process, while higher rates were in patients with the triple-negative breast cancer (16,2 ± 2,8 cm/sec) and luminal B type (15,9 ± 3,9 cm/sec). While luminal A type had ACBFL 14,2 ± 2,6 cm/sec and HER2(+) had 14,6 ± 2,5 cm/sec. IR in all subgroups was 0,73 ± 0,12, that matches the sharply increased values, and shows an increase peripheral resistance in vessels. IP was 12,35 ± 1,75, that reflects the amplified elastic and flexible properties of the newly formed blood vessels. Effect of AC-nPCT was higher in patients with the luminal B type (CR – 5, PR – 3). In patients with triple-negative BC effect of nPCT was worse, despite the high rate of BF in the tumor (PR – 1, stabilization – 6, progression – 2). In patients with low rate of BF in the tumor (luminal A, HER2(+) type) effect was the worst (PR – 2, stabilization – 7, progression – 4 patients in both groups). The correlation coefficient was statistically significant for BF as increased ACBFV, IR, IP, and the frequency of CR + PR to nPCT of luminal B type. Conclusions There is a correlation between the velocity of BF and degree of destruction of tumor by cytostatics. While the rate of BF depended on the molecular type of the tumor and did not depend on the size of the primary tumor. Disclosure All authors have declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
